Teqqa launches Precision Antibiotic Therapy (PAT™) to tackle antibiotic resistance globally

PAT applies predictive analytics and big data to deliver optimized patient-specific antibiotic guidance in real time

JACKSON HOLE, WY. (February 17, 2017) – Teqqa LLC announced today the launch of Precision Antibiotic Therapy (PAT), breakthrough technology developed to help physicians prescribe personalized antibiotic therapy for patients based on their specific conditions and history.  Among the factors PAT uses are the patient’s age, gender, medical conditions, allergies, illness severity, location, recent antibiotic exposures, and previous culture and susceptibility results.

“We founded Teqqa to address the growing issues with antibiotic resistance, applying precision medicine principles to infectious disease,” said Dan Peterson, MD, MPH, CEO and Founder of Teqqa.  “Precision Medicine to this point has been almost all about cancer therapy. Precision Antibiotic Therapy (PAT) extends that paradigm and puts this functionality at physicians’ fingertips real-time to improve outcomes for some of the deadliest, costliest, and most common conditions in healthcare, including sepsis, pneumonia, and UTI.  The antibiograms that hospitals currently have are done once a year, are not predictive, and are not patient specific.  That’s not nearly good enough.”

“Teqqa is transforming how we treat infectious diseases,” said Keith Hamilton, MD, Associate Healthcare Epidemiologist and Director of Antimicrobial Stewardship at the Hospital of the University of Pennsylvania. “Our providers can view patient-specific antibiotic recommendations, collaborate as needed with our stewardship team, and opt to be notified when new information indicates a change in therapy may be warranted - all from the Teqqa app on their smartphone.”

PAT is a real-time application specifically designed to optimize antibiotic therapy for each patient, thereby reducing antibiotic resistance in populations overall. It is available as a smartphone app or on the web app.  Other Teqqa technologies also enable

  • Alerts and rapid diagnostic results sent directly to clinicians in real-time
  • Real-time collaboration between stewardship teams and providers
  • Historic tracking of providers’ actions, with correlation to patient outcomes
  • Reporting on clinical improvements and financial savings.

Visit booth #6690 at HIMSS17 to learn more.

About Teqqa

Teqqa is the healthcare technology leader in improving infectious disease outcomes.  Through its software and mobile applications, Teqqa helps hospitals optimize antibiotic use and combat antimicrobial resistance. Teqqa also provides robust analytics to clinical data, allowing clinical teams to focus on problems, measure outcomes, and evaluate progress.  At the University of Pennsylvania, Penn Medicine relies on Teqqa tools to power their antimicrobial stewardship program.  For more information on Teqqa’s solutions, visit www.teqqa.com or email contact@teqqa.com.

Innovative Antibiogram Drives 100x Increase in Use

In February 2014, Teqqa (www.teqqa.com) announced an interactive antibiogram, done in partnership with the University of Pennsylvania Health System (UPHS) .  The 'iAntibiogram' delivers timely, focused information to providers using a smartphone-enabled platform, up-to-date susceptibility results, inclusion of drug information and clinical guidelines, and ability to drill down on susceptibility by looking at specific specimen source, facility, and ICU.

The iAntibiogram seeks to increase provider engagement and improve prescribing choices.  Since the launch of the iAntibiogram, the University of Pennsylvania has seen a 100x increase in usage compared with the previous antibiogram.  The iAntibiogram delivers data directly to the physicians' smartphones, replacing the former practice of providing static data to clinicians once a year.

Since launching the iAntibiogram, early findings include:

  • Over 700 unique users in the health system have logged in.
  • The iAntibiogram has seen 9000+ unique sessions.
  • On average, each unique user has utilized the iAntibiogram over a dozen times.
  • The average number of page views per iAntibiogram session is 5.09.
  • When viewing susceptibility by bug class, users view gram positive 42% of the time and gram negative 58% of the time.
  • The top 5 drug information pages viewed were Amoxicillin-Clavulanate, Daptomycin, Amikacin, Ceftazidime, and Linezolid.

 “The Teqqa apps are now engrained in our antimicrobial stewardship process, providing us with quick access to data and resistance patterns to inform our physicians’ prescribing decisions,” said Keith Hamilton, M.D., associate healthcare epidemiologist and director of antimicrobial stewardship at the Hospital of the University of Pennsylvania. “Physician usage of antibiograms has grown exponentially since we instituted the Teqqa iAntibiogram: from an average of 28 views a month of our web-based static antibiogram to an average of 3,900 views per month of the Teqqa iAntibiogram.  It is now a part of how we deliver top patient care.” 

About Teqqa

Teqqa's mission is to partner with healthcare institutions to optimize antibiotic use.  Their comprehensive product improves care through clinical decision support, analytics, and work tools.  To learn more, visit www.teqqa.com/mission.

 

Teqqa Partners with CDC Get Smart About Antibiotics Week 2015

From November 16-22, 2015, Teqqa is a partner of the CDC Get Smart About Antibiotics Week campaign.

 

Teqqa Announces Next-Generation Antibiotic Stewardship Technology at University of Pennsylvania Health System

Teqqa LLC, a software firm specializing in applications that optimize antibiotic use, announced today that the University of Pennsylvania Health System (UPHS) has contracted to extend and expand its use of Teqqa applications in all UPHS hospitals.

Teqqa LLC Wins Hero Award from Investors at Silicon Couloir Pitch Day

Teqqa LLC, a software firm specializing in applications that optimize antibiotic use, presented to a panel of experienced investors at the Silicon Couloir Pitch Day and won the contest’s top prize, the Hero Award.

Teqqa Provides the Clinical Decision Support to Rapid Diagnostic Results to Drive Changes in Treatment and Outcomes

Teqqa LLC, a company specializing in helping healthcare systems optimize antibiotic use to combat the growing problem of resistance, today announced that it will showcase its Teqqa product suite and how it leverages the new developments in rapid diagnostic testing at the ASM 2015 General Meeting in New Orleans (Exhibit booth #566).

Penn Medicine, Teqqa LLC Developing New Software and App to Track Antibiotic Resistance

Penn Medicine today announced a collaboration with software and analytics company Teqqa, LLC that could revolutionize the way antibiotics are tracked and prescribed in clinical settings.